The putative catalytic role of higher serotonin bioavailability in the clinical response to exposure and response prevention in obsessive-compulsive disorder

Revista Brasileira de Psiquiatria

Volumn 38, Issue 4, 2016, Pages 287-293

  Sampaio, Thiago ^a   Lima, Cristiane ^a   Corregiari, Fabio ^a   Bernik, Marcio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Behavior therapy; Biological markers; Neurophysiology; Obsessive compulsive disorder; Stress

Indexed keywords

SEROTONIN; BIOLOGICAL MARKER; SEROTONIN AGONIST;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; BEHAVIOR THERAPY; BIOAVAILABILITY; BLOOD ANALYSIS; CLAUSTROPHOBIA; CLINICAL ARTICLE; COMORBIDITY; DEPRESSION; DSM-IV-TR; ENZYME ACTIVITY; EXPOSURE AND RESPONSE PREVENTION; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MALE; MEDICAL PROCEDURES; NEUROPHYSIOLOGY; OBSESSIVE COMPULSIVE DISORDER; PATIENT RATED ANXIETY SCALE; SHEEHAN DISABILITY SCALE; SOCIAL PHOBIA; STRESS; THROMBOCYTE RICH PLASMA; TREATMENT RESPONSE; YALE BROWN OBSESSIVE COMPULSIVE SCALE; ADOLESCENT; AGED; AVERSION THERAPY; BLOOD; CHEMISTRY; COGNITIVE THERAPY; FOLLOW UP; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PROCEDURES; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; THROMBOCYTE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AVERSIVE THERAPY; BIOMARKERS; BLOOD PLATELETS; COGNITIVE THERAPY; DEPRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN; SEROTONIN RECEPTOR AGONISTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84994572045     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/1516-4446-2015-1721     Document Type: Article

References (30)

1. Ponniah K, Magiati I, Hollon SD. An update on the efficacy of psychological therapies in the treatment of obsessive-compulsive disorder in adults. J Obsessive Compuls Relat Disord. 2013; 2: 207-18.
2. National Collaborating Centre for Mental Health. Obsessivecompulsive disorder: core interventions in the treatment of obsessivecompulsive disorder and body dysmorphic disorder. Leicester: British Psychological Society; 2006.
3. Lewin AB, Wu MS, McGuire JF, Storch EA. Cognitive behavior therapy for obsessive-compulsive and related disorders. Psychiatr Clin North Am. 2014; 37: 415-45.
4. Lack CW. Obsessive-compulsive disorder: evidence-based treatments and future directions for research. World J Psychiatry. 2012; 2: 86-90.
5. Graeff FG. On serotonin and experimental anxiety. Psychopharmacology (Berl). 2002; 163: 467-76.
6. Mobbs D, Petrovic P, Marchant JL, Hassabis D, Weiskopf N, Seymour B, et al. When fear is near: threat imminence elicits prefrontal- periaqueductal gray shifts in humans. Science. 2007; 317: 1079-83.
7. Dold M, Aigner M. [Neuroimaging the various symptom dimensions of obsessive-compulsive disorder]. Neuropsychiatr. 2009; 23: 193-205.
8. Murphy DL, Moya PR, Fox MA, Rubenstein LM, Wendland JR, Timpano KR. Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneity. Philos Trans R Soc Lond B Biol Sci. 2013; 368: 20120435.
9. McNaughton N, Andrews G. Anxiety. Dunedin: University of Otagosemi; 1990.
10. Graeff FG, Guimarães FS, De Andrade TG, Deakin JF. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav. 1996; 54: 129-41.
11. Gray JA, McNaughton N. The neuropsychology of anxiety: an enquiry into the functions of the septo-hippocampal system. 2nd ed. Oxford: Oxford University; 2000.
12. Abramowitz JS, Taylor S, McKay D. Obsessive-compulsive disorder. Lancet. 2009; 374: 491-9.
13. Foa EB, Kozak MJ. Emotional processing of fear: exposure to corrective information. Psychol Bull. 1986; 99: 20-35.
14. Rapoport JL. Recent advances in obsessive-compulsive disorder. Neuropsychopharmacology. 1991; 5: 1-10.
15. Pletscher A, Laubscher A. Blood platelets as models for neurons: uses and limitations. J Neural Transm Suppl. 1980; 16: 7-16.
16. Da Prada M, Cesura AM, Launay JM, Richards JG. Platelets as a model for neurones? Experientia. 1988;44: 115-26.
17. Celada P, Martín F, Artigas F. Effects of chronic treatment with dexfenfluramine on serotonin in rat blood, brain and lung tissue. Life Sci. 1994; 55: 1237-43.
18. Bianchi M, Moser C, Lazzarini C, Vecchiato E, Crespi F. Forced swimming test and fluoxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes. Exp Brain Res. 2002; 143: 191-7.
19. Koudouovoh-Tripp P, Sperner-Unterweger B. Influence of mental stress on platelet bioactivity. World J Psychiatry. 2012; 2: 134-47.
20. Humble M, Bejerot S, Bergqvist PB, Bengtsson F. Reactivity of serotonin in whole blood: relationship with drug response in obsessivecompulsive disorder. Biol Psychiatry. 2001; 49: 360-8.
21. Delorme R, Chabane N, Callebert J, Falissard B, Mouren-Siméoni MC, Rouillon F, et al. Platelet serotonergic predictors of clinical improvement in obsessive compulsive disorder. J Clin Psychopharmacol. 2004; 24: 18-23.
22. First MB. Structured clinical interview for DSM-IV-TR Axis I disorders: patient editionNew York: Columbia University; 2005.
23. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23: 56-62.
24. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry. 1989; 46: 1012-6.
25. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59: 22-33;quiz 4-57.
26. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996; 11: 89-95.
27. Tolin DF, Abramowitz JS, Diefenbach GJ. Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown obsessive compulsive scale. J Clin Psychiatry. 2005; 66: 1549-57.
28. Baer L. Behavior therapy: endogenous serotonin therapy? J Clin Psychiatry. 1996;57: 33-5.
29. Graeff FG. Neuroanatomy and neurotransmitter regulation of defensive behaviors and related emotions in mammals. Braz J Med Biol Res. 1994; 27: 811-29.
30. Hewlett WA, Vinogradov S, Martin K, Berman S, Csernansky JG. Fenfluramine stimulation of prolactin in obsessive-compulsive disorder. Psychiatry Res. 1992; 42: 81-92.